Showing 3911-3920 of 7016 results for "".
- Extended Analysis Confirms Favorable Safety for Upadacitinibhttps://reachmd.com/news/extended-analysis-confirms-favorable-safety-upadacitinib/2470761/Results from a long-term integrated analysis support the favorable safety profile of upadacitinib for moderate-to-severe atopic dermatitis (AD) in adolescents and adults. The analysis, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, included over 9,000 patient-y
- TEMPO-3 Trial: Tavapadon Adjunctive Therapy in Fluctuating Parkinson Diseasehttps://reachmd.com/news/tempo-3-trial-tavapadon-adjunctive-therapy-in-fluctuating-parkinson-disease/2487430/Key Takeaways Adjunctive tavapadon was associated with more daily good-on-time and less off-time than placebo at week 26 in adults receiving stable levodopa. Adverse events and adverse-event-related discontinuations were more frequent with tavapadon, w
- Evaluating Lenacapavir and bNAbs in HIV-1https://reachmd.com/news/lenacapavir-bnabs-hiv-1/2487075/Key Takeaways Week-26 virologic control was broadly similar between a long-acting regimen and continued oral ART in this phase 2 comparison. Adverse-event rates were broadly comparable after excluding injection-site reactions, and no serious adverse ev
- Early and Sustained Depemokimab Efficacy in Type 2 Asthmahttps://reachmd.com/news/early-and-sustained-depemokimab-efficacy-in-type-2-asthma/2486867/Key Takeaways Depemokimab was associated with fewer first exacerbations than placebo over 52 weeks, and benefit appeared by week 4. Improvements were reported across each 26-week dosing period in symptom and quality-of-life measures, with sustained res
- Ravulizumab in IgA Nephropathy: Phase 2 Trial Readouthttps://reachmd.com/news/ravulizumab-in-iga-nephropathy-phase-2-trial-readout/2486671/Key Takeaways During the randomized period, ravulizumab was associated with a greater reduction in proteinuria than placebo at week 26 (−41.9% vs −16.8%; treatment effect 30.1%; P = 0.005). Investigators reported a trend toward eGFR stabilization (leas
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://reachmd.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://reachmd.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://reachmd.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- C-Path Launches Consortium for Alpha-1 Antitrypsin Deficiencyhttps://reachmd.com/news/c-path-launches-consortium-for-alpha-1-antitrypsin-deficiency/2462474/TUCSON, Ariz., March 26, 2024 — Critical Path Institute (C-Path) is excited to announce the launch of the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) Consortium. The CPA-1 consortium aims to accelerate drug developm
- Patient Advocacy Groups Spotlight Gaps and Resources in Women’s Healthhttps://reachmd.com/news/patient-advocacy-groups-spotlight-gaps-and-resources-in-womens-health/2483474/New York, NY – At the 2025 Women’s Health Annual Visit (WHAV), the final session brought forward a powerful discussion centered on the voices of patient advocacy leaders. Representatives from the Well Project, the National Menopause Foundation, and the Fibroid Fo